Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Catalent Inc
(NY:
CTLT
)
60.83
+1.17 (+1.96%)
Streaming Delayed Price
Updated: 11:37 AM EST, Nov 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Catalent Inc
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
Catalent, Inc. Reports First Quarter Fiscal 2025 Results
November 05, 2024
From
Catalent, Inc.
Via
Business Wire
Roche's Q3 Sales Surge Led By Ocrevus, Vabysmo, Urges Regulators To Block Novo Holdings' $16.5B Catalent Acquisition
October 23, 2024
Roche reported a 9% increase in third-quarter sales, driven by strong performance from Ocrevus and Vabysmo. Roche also raised concerns over the Catalent acquisition.
Via
Benzinga
Catalent Issues Open Letter to Customers Regarding Pending Acquisition by Novo Holdings
October 21, 2024
From
Catalent, Inc.
Via
Business Wire
After US Senator, Unions Urge Federal Trade Commission To Block Novo's $16.5B Acquisition Of Catalent
October 18, 2024
Public interest groups are urging the FTC to block Novo Holdings' $16.5 billion acquisition of Catalent, citing concerns over reduced competition in critical areas like diabetes, obesity treatments,...
Via
Benzinga
Beyond The Numbers: 6 Analysts Discuss Catalent Stock
April 04, 2024
Via
Benzinga
Jim Cramer: 'We Need More Uranium,' Recommends This Stock; Says Novo Nordisk 'Doesn't Hold A Candle' To Big Pharma Rival
October 15, 2024
Jim Cramer believes Uranium Energy Corp. is going higher, thanks to a recent acquisition deal. Novo Nordisk faces antitrust concerns while Halliburton gets a Buy rating from BofA Securities.
Via
Benzinga
Catalent Signs Agreement to Sell Somerset, NJ Oral Solids Facility
October 14, 2024
From
Catalent, Inc.
Via
Business Wire
FTC Faces Pressure to Block Novo Nordisk-Catalent Merger Over Antitrust Fears
October 10, 2024
Concerns are rising as Novo Nordisk's $16.5 billion bid to acquire Catalent faces scrutiny from the FTC. Critics argue the merger could harm competition in the GLP-1 market, potentially driving up...
Via
Benzinga
Four Stocks To Watch This Week - Tuesday, Oct. 01
October 01, 2024
A flat week that was anticipated, one notable event was China's stimulus package announcement, which sent China-related stocks soaring. Most of these stocks surged without prior consolidations/warning...
Via
Talk Markets
Tempus AI Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating
September 16, 2024
A Relative Strength Rating upgrade for Tempus AI shows improving technical performance.
Via
Investor's Business Daily
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Catalent, Inc. Reports Fourth Quarter and Fiscal 2024 Results
August 29, 2024
From
Catalent, Inc.
Via
Business Wire
Prediction: Up 74% So Far This Year, This Weight Loss Stock Is About to Crater
August 16, 2024
A small telemedicine company just entered the weight loss race.
Via
The Motley Fool
Catalent Completes $25 Million Expansion of its Clinical Supply Facility in Schorndorf, Germany
July 16, 2024
From
Catalent, Inc.
Via
Business Wire
Sarepta's Expanded Approval Unlikely To Influence Novo Holdings' Acquisition of Catalent, But Provides Investor Protection Amid Uncertainty
June 21, 2024
Catalent shares rise after Sarepta Therapeutics' Elevidys expanded approval. Despite uncertainties, Catalent's risk/reward profile improves.
Via
Benzinga
S&P 500 Giants Lead Five Healthy Stocks Near Buy Points
June 01, 2024
Eli Lilly is in a buy zone, while rival Novo Nordisk forged a lower entry.
Via
Investor's Business Daily
Topics
Stocks
Exposures
US Equities
Catalent Stockholders Approve Transaction with Novo Holdings
May 29, 2024
From
Catalent, Inc.
Via
Business Wire
Soaring Eli Lilly Stock Could Climb Another 24% According to a Wall Street Analyst. Is the Stock a Buy Now?
May 28, 2024
Plowing $9 billion into a manufacturing facility could help a successful tirzepatide launch reach new heights.
Via
The Motley Fool
Hedge Funds Tweak Portfolios In Q1: Marvell, TD Synnex, AES Get More Love As Focus Shifts To AI
May 24, 2024
Hedge funds are looking for high-return opportunities beyond the mega-cap tech giants preferring to focus on cyclical sectors and AI.
Via
Benzinga
CTLT Stock Earnings: Catalent Misses EPS, Misses Revenue for Q3 2024
May 09, 2024
CTLT stock results show that Catalent missed analyst estimates for earnings per share and missed on revenue for the third quarter of 2024.
Via
InvestorPlace
Catalent, Inc. Reports Third Quarter Fiscal 2024 Results
May 08, 2024
From
Catalent, Inc.
Via
Business Wire
Demand Soars For Novo Nordisk's Weight-Loss Drug Wegovy Despite Supply Constraints And Eli Lilly Competition
May 02, 2024
The Danish pharmaceutical company is now shipping more introductory doses of Wegovy to the U.S., as it grapples with supply constraints and competition from Eli Lilly.
Via
Benzinga
Robbins LLP Reminds Stockholders it is Investigating the Acquisition of Catalent, Inc. (CTLT)
April 17, 2024
From
Robbins LLP
Via
Business Wire
Novo Nordisk's Dominance In Obesity & Diabetes Drug Market Backed by Strong Pipeline: Analyst Gives Outperform Rating
April 12, 2024
BMO's coverage of Novo Nordisk, spotlighting its groundbreaking advancements in weight loss and diabetes drugs. Analysts foresee Novo and Eli Lilly maintaining dominance in the obesity market, fueled...
Via
Benzinga
Robbins LLP is Investigating the Acquisition of Catalent, Inc. (CTLT) by Novo Holdings
April 10, 2024
From
Robbins LLP
Via
GlobeNewswire
Best Obesity Drug Stock: Eli Lilly, Novo Nordisk, or Viking Therapeutics?
March 26, 2024
All three of these high-flying stocks could have more room to run.
Via
The Motley Fool
Week In Review: Three Multinationals Plan Investments In Southeast Asia Facilities
March 23, 2024
Shanghai WuXi Biologics has broken ground on a $1.4 billion facility in Singapore. Meanwhile, Novo Nordisk announced plans to invest $556 million to expand its Tianjin city production facility.
Via
Talk Markets
Did Novo Nordisk Just Get a Jump on Eli Lilly?
March 19, 2024
A recent FDA announcement may have just put one company in the lead.
Via
The Motley Fool
Exposures
Product Safety
The Top 3 Pharma Stocks to Buy in March2024
March 09, 2024
Investors explore the top three biotechnology stocks to buy in 2024 which are leading the anti-obesity market surge.
Via
InvestorPlace
Novo Nordisk Sets Timeframe For Its Next-Gen Experimental Obesity Drug
March 08, 2024
"Novo Nordisk's optimism soars with promising early trial data for amycretin, an experimental weight loss pill. Expect significant weight loss and cardiovascular benefits. Phase 2 trial begins in late...
Via
Benzinga
Catalent Publishes Fifth Annual Corporate Responsibility Report, Highlighting Progress and Reinforcing Long-Term Commitment
March 07, 2024
From
Catalent, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.